Knowledge HQ
Explore our comprehensive collection of scientific resources, from application notes and case studies to videos and webinars.
Share
Filter By
Cell Types
Filter by Year
Publications
B Cells
Adversarial learning breakthrough enables real-time AI security
The emergence of AI-driven attacks – utilising reinforcement learning (RL) and Large Language Model (LLM) capabilities – has created a class of “vibe hacking” and adaptive threats that mutate faster than human teams can respond. This represents a governance and operational risk for enterprise leaders that policy alone cannot mitigate.
Publications
CTL, cytotoxic_t_lymphocyte, pbms, T-Cells
Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections
This study describes a rapid (10-day) method using the **G-Rex system** and peptide stimulation to generate polyclonal (CD4+ and CD8+) **Cytotoxic T Lymphocytes (CTL)** specific for 15 antigens from 7 viruses (EBV, CMV, Adv, BK, HHV-6, RSV, and Influenza). PBMCs were stimulated with a pooled peptide mixture (pepmix) in the presence of prosurvival cytokines **IL-4 and IL-7**. This method supports the selective expansion of polyclonal, **Th1-polarized T cells**, resulting in polyfunctional CTLs producing IFN-γ and TNF-α. Phenotypic analysis indicated that the CTLs were predominantly CD4+ (74.3%) with a minor CD8+ component (22.8%), similar to those generated conventionally. Importantly, the pepmix/G-Rex approach yielded CTLs with comparable **epitope breadth, T-cell receptor (TCR) avidity**, and expression of memory and activation markers (CD62L, CD28, CD45RO) compared to CTLs generated using plasmid-activated dendritic cells. The protocol efficiently manufactures large numbers within 10 days from minimal starting material, providing a cost-effective broad spectrum antiviral agent.
Publications
K562, T-Cells
Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma
This is a placeholder 2 summary for the resource. Replace this text with the article abstract or a short description.
Publications
T-Cells, TIL, tumor_infiltrating_lymphocyte
Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable Flasks to Numbers Needed for Patient Treatment
This study simplifies Tumor Infiltrating Lymphocyte (TIL) production for adoptive cell therapy using **G-Rex gas-permeable flasks** (G-Rex10 for initiation, G-Rex100 for rapid expansion protocol [REP]). TIL initiation in G-Rex10 yielded comparable or superior growth compared to 24-well plates. The two-step REP using G-Rex100 flasks routinely produced clinical doses (approx 25–60 billion cells), requiring approximately **9–10L of media**, representing a 3–4 fold reduction compared to traditional flask/bag REP methods (30–40L). The final TIL product maintained a high cell concentration (mean $7.95 imes 10^6$ cells/mL). Critically, the **phenotype** (CD3, CD8 expression) and **function** (IFN-γ production in response to anti-CD3 or autologous tumor) of TIL expanded in G-Rex flasks were determined to be **similar** to TIL generated using conventional flask/bag methods. This simplified, semi-closed G-Rex method reduces the complexity, labor, and resource requirements (media, incubator space, specialized equipment) associated with GMP TIL production.
Literature
Ready to Use Cytokines -Closed System
Speed up your immune cell therapy manufacturing with Ready-to-Use GMP Cytokines. Now available in three convenient formats—ProPak closed system bags, process-sized vials, and liquid formulations—these high-quality cytokines eliminate unnecessary steps, reduce handling errors, and ensure consistency in your workflow. Whether you’re optimizing T cell expansion or streamlining cytokine delivery, our animal-free GMP and RUO proteins are designed for efficiency and reliability. Download this flyer to see how you can enhance your process and accelerate your path to the clinic with ease.
Literature
NK Media Flyer – Accelerate Development
Unlock the full potential of NK cell therapies with ExCellerate™ NK Cell Expansion Media—a cutting-edge, animal-free solution designed to streamline your research and clinical applications. Whether you’re working with iPSC-derived NK cells, PBMCs, or purified NK cells, this innovative media ensures robust expansion, sustained viability, and optimized cytotoxic function without the complexities of traditional serum-based systems. Ready to accelerate your NK cell research with a simplified, high-performance solution? Download the flyer now to see how ExCellerate™ can enhance your workflow and drive better results.
Videos
ATW 2025 ScaleReady and Ignacio Nunez COO CellReady with Cellular Origins – Key Partnerships in CGT
Ignacio Nunez discusses the importance of collaboration and partnerships, such as that between ScaleReady and Cellular Origins, and the impact of these on drug development and patient accessibility.
Videos
G-Rex vs Rocking Motion Bio-Reactors
The best technology is often the simplest. Quiet, elegant, brilliant. A revolution in T-Cell culture technology. The G-Rex Bioreactor.
Application Notes
Fill and Forget Application Note
Discover a game-changing approach to T cell expansion. This application note showcases how the G-Rex bioreactor and Bio-Techne reagents deliver hands-free, zero-touchpoint cell growth. Learn how to streamline your manufacturing, boost efficiency, and maintain cell health—all with a simple fill-and-forget workflow.
Videos
Ignacio Núñez, COO, CellReady, Discusses Sustainability in Cell Therapy at ISCT 2024
Ignacio Nunez, COO of CellReady, discusses the importance of sustainability in cell and gene therapy manufacturing at ISCT 2024.
Videos
Ignacio Núñez, COO, CellReady, Discusses Current Projects at ASGCT 2024
Ignacio Nunez, COO of CellReady, discusses current projects and what the future holds during ASGCT 2024.